Recently, Genentech (Genentech), a subsidiary of Roche (RHHBY.US), announced that its major antibody therapy Ocrevus obtained positive data in the phase 3 clinical study Ocarina II for the treatment of recurrent or primary progressive multiple sclerosis (RMS or PPMS). The results showed that the Ocrevus subcutaneous preparation, which only took two doses a year, almost completely suppressed clinical recurrence and brain lesions.
罗氏(RHHBY.US)重磅抗体疗法Ocrevus3期临床获得积极数据
Phase 3 clinical trial of Roche (RHHBY.US) major antibody therapy Ocrevus obtained positive data
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.